منابع مشابه
Crash development of AIDS test nears goal.
Impending development of a blood test for AIDS has paved the way for an epidemiological study by the National Heart, Lung and Blood Institute. Blood samples from 200,000 presumably healthy donors will soon be drawn and stored, to be screened when the test becomes available. Donors and recipients of blood which tests AIDS-positive will then be followed to see if AIDS develops. The study raise...
متن کاملMEK Inhibitor U0126 Reverses Protection of Axons from Wallerian Degeneration Independently of MEK–ERK Signaling
Wallerian degeneration is delayed when sufficient levels of proteins with NMNAT activity are maintained within axons after injury. This has been proposed to form the basis of 'slow Wallerian degeneration' (Wld (S)), a neuroprotective phenotype conferred by an aberrant fusion protein, Wld(S). Proteasome inhibition also delays Wallerian degeneration, although much less robustly, with stabilizatio...
متن کاملPreclinical Development Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212
The MEK1 and MEK2 inhibitor GSK1120212 is currently in phase II/III clinical development. To identify predictive biomarkers, sensitivity toGSK1120212was profiled for 218 solid tumor cell lines and 81 hematologic malignancy cell lines. For solid tumors, RAF/RAS mutation was a strong predictor of sensitivity. Among RAF/RAS mutant lines, co-occurring PIK3CA/PTEN mutations conferred a cytostatic re...
متن کاملPanniculitis Associated with MEK Inhibitor Therapy: An Uncommon Adverse Effect
The combination of MEK inhibitor (cobimetinib, trametinib) and BRAF inhibitor (vemurafenib, dabrafenib) is now the first-line treatment in patients with BRAF V600-mutated metastatic melanoma. This association reduces cutaneous adverse events induced by BRAF inhibitors alone, including photosensitivity, hand-foot syndrome, hyperkeratosis, alopecia, skin papillomas, keratoacanthomas, and squamous...
متن کاملTrametinib: a MEK inhibitor for management of metastatic melanoma
This review presents the current data on the efficacy and safety of the selective mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor trametinib in patients with metastatic BRAF V600-positive melanoma. The pharmacological, safety, and efficacy data come from the Phase I, II, and III studies of trametinib monotherapy, as well as those in combination with the BRAF inhibitor da...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Biotechnology
سال: 2013
ISSN: 1087-0156,1546-1696
DOI: 10.1038/nbt0113-4